334 related articles for article (PubMed ID: 32904650)
1. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
Liu KC; Hao YH; Lv WF; Jia WD; Ji CS; Zhou CZ; Cheng DL; Xu SB; Gao ZG; Su MX; Shi CS
Drug Des Devel Ther; 2020; 14():3461-3468. PubMed ID: 32904650
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma.
Chen S; Yu W; Zhang K; Liu W
BMC Cancer; 2018 Nov; 18(1):1131. PubMed ID: 30453925
[TBL] [Abstract][Full Text] [Related]
3. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review.
Mulyadi R; Hasan I; Sidipratomo P; Putri PP
J Egypt Natl Canc Inst; 2024 May; 36(1):18. PubMed ID: 38797810
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
Choi GH; Shim JH; Kim MJ; Ryu MH; Ryoo BY; Kang YK; Shin YM; Kim KM; Lim YS; Lee HC
Radiology; 2013 Nov; 269(2):603-11. PubMed ID: 23864102
[TBL] [Abstract][Full Text] [Related]
8. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
[TBL] [Abstract][Full Text] [Related]
9. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma.
Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
J Dig Dis; 2020 May; 21(5):287-292. PubMed ID: 32315498
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population.
Lee SW; Tung CF; Peng YC; Lien HC; Chang CS
J Dig Dis; 2020 Aug; 21(8):462-467. PubMed ID: 32472590
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
14. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Yokosuka O; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y;
Gut; 2020 Aug; 69(8):1492-1501. PubMed ID: 31801872
[TBL] [Abstract][Full Text] [Related]
15. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Li D; Pang Y; Xu L; Xu X
J BUON; 2021; 26(4):1355-1364. PubMed ID: 34564992
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma.
Kaibori M; Matsushima H; Ishizaki M; Kosaka H; Matsui K; Kariya S; Yoshii K; Sekimoto M
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1217-1224. PubMed ID: 33906315
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.
Qu XD; Chen CS; Wang JH; Yan ZP; Chen JM; Gong GQ; Liu QX; Luo JJ; Liu LX; Liu R; Qian S
BMC Cancer; 2012 Jun; 12():263. PubMed ID: 22721173
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of sorafenib combined with transcatheter hepatic arterial chemoembolization in treating intermediate-advanced hepatocellular carcinoma.
Kuang J; Wan D; Wan P; Wu D
J BUON; 2021; 26(3):868-874. PubMed ID: 34268947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
